Related references
Note: Only part of the references are listed.Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee
Joseph Bubalo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma
S. R. Parmar et al.
BONE MARROW TRANSPLANTATION (2014)
A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function
Muneer H. Abidi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation
Ulas D. Bayraktar et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myelotha: A Matched Comparison to a Melphalan-Only Approach
Margarita Blanes et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Pancytopenia following vivax malaria in a CLL patient
Prashant Sharma et al.
BLOOD (2013)
Cellular immunotherapy for plasma cell myeloma
A. L. Garfall et al.
BONE MARROW TRANSPLANTATION (2013)
Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma
Rakesh Popat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy
Jonathan L. Kaufman et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Current treatments for renal failure due to multiple myeloma
Efstathios Kastritis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial
Susan G. Kreissman et al.
LANCET ONCOLOGY (2013)
Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma
Donna Reece et al.
ONCOLOGIST (2013)
Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
Mirta Kozelj et al.
RADIOLOGY AND ONCOLOGY (2013)
PHASE IIA, OPEN-LABEL, RANDOMIZED, PHARMACOKINETIC COMPARATIVE, CROSS-OVER STUDY OF MELPHALAN HCL FOR INJECTION (PROPYLENE GLYCOL-FREE) AND ALKERAN FOR INJECTION FOR MYELOABLATIVE CONDITIONING IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION
O. S. Aljitawi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
HIGHER MELPHALAN EXPOSURE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL FOR MYELOMA PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT
P. J. Shaw et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
Taiga Nishihori et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid
Manish Sharma et al.
CANCER (2012)
Genetic variations in multiple myeloma II: association with effect of treatment
Annette Vangsted et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Dan T. Vogl et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
Maria Teresa Cibeira et al.
BLOOD (2011)
New developments in conditioning regimens before auto-SCT in multiple myeloma
P. Moreau et al.
BONE MARROW TRANSPLANTATION (2011)
Monoclonal antibodies in the treatment of multiple myeloma
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma
Rolf W. Sparidans et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2011)
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
Angela Dispenzieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
ACTUAL WEIGHT TO CALCULATE SURFACE AREA PROVIDES THE BEST ESTIMATE OF AUC FOR MELPHALAN IN MYELOMA
P. J. Shaw et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
Antonio Palumbo et al.
BLOOD (2010)
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
Murielle Roussel et al.
BLOOD (2010)
Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
C. Dumontet et al.
BONE MARROW TRANSPLANTATION (2010)
Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction
M. Rosenzweig et al.
BONE MARROW TRANSPLANTATION (2010)
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
Christa E. Nath et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study
Sagar Lonial et al.
CLINICAL CANCER RESEARCH (2010)
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
Richard A. Campbell et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
Juan Jose Lahuerta et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Increased Plasma-Immune Cytokines throughout the High-Dose Melphalan-Induced Lymphodepletion in Patients with Multiple Myeloma: A Window for Adoptive Immunotherapy
Maud Condomines et al.
JOURNAL OF IMMUNOLOGY (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)
H. Miles Prince et al.
BLOOD (2009)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Population Pharmacokinetics of Melphalan and Glutathione S-transferase Polymorphisms in Relation to Side Effects (vol 83, pg 749, 2008)
A. Kuehne et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
An Isocratic UV HPLC Assay for Analysis of Total and Free Melphalan Concentrations in Human Plasma
C. E. Nath et al.
ACTA CHROMATOGRAPHICA (2008)
Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial
Muzaffar H. Qazilbash et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
28 years of high-dose therapy and SCT for neuroblastoma in Europe:: lessons from more than 4000 procedures
R. Ladenstein et al.
BONE MARROW TRANSPLANTATION (2008)
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma
Luciano J. Costa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Therapeutic drug monitoring of busulfan in transplantation
J. A. Russell et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
Samo Zver et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later
Hillard M. Lazarus et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects
A. Kuehne et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients
Christa E. Nath et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with 166Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma.: Impact on transplant outcomes
Anna V. Christoforidou et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
Klaus Podar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model
M. L. Grazziutti et al.
BONE MARROW TRANSPLANTATION (2006)
Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy:: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival
K Carlson
BONE MARROW TRANSPLANTATION (2005)
High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European neuroblastoma study group
J Pritchard et al.
PEDIATRIC BLOOD & CANCER (2005)
Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation
CE Nath et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Pharmacokinetics of high-dose chemotherapy
Y Nieto et al.
BONE MARROW TRANSPLANTATION (2004)
Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study
GL Phillips et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2004)
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
MA Gertz et al.
BONE MARROW TRANSPLANTATION (2004)
Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies
P Mougenot et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma:: results of two phase 1/2 trials
S Giralt et al.
BLOOD (2003)
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma
RK Dasgupta et al.
BLOOD (2003)
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
P Moreau et al.
BLOOD (2002)
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
A Badros et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma
G Vassal et al.
BONE MARROW TRANSPLANTATION (2001)
Share Paper
